Darunavir

ARV U.S. Brand Name

Prezista

ARV Abbreviation(s)

DRV

U.S. FDA Label

Darunavir Labeling (Package Insert)

ARV Class

Protease Inhibitors

First U.S. Approval

December 16, 2011

U.S. Manufacturer

Janssen

Formulations

Strength	Formulation	Image	Description	Boosted
DRV 800 mg, COBI 150 mg	Film-Coated Tablets	X	Pink, oval-shaped, film-coated tablets debossed with "800" on one side and "TG" on the other side	Yes
800 mg	Film-Coated Tablets	X	Dark red oval tablet with imprint of 800 on one side and T on the other	No
600 mg	Film-Coated Tablets	X	Orange oval tablet with imprint of 600MG on one side and TMC on the other.	No
150 mg	Film-Coated Tablets	X	White oval tablet with imprint of 150 one side and TMC on the other.	No
75 mg	Film-Coated Tablets	X	White oval tablet with imprint of 75 on one side and TMC on the other.	No
100 mg in 1 mL	Oral Suspension	X	White to off-white strawberry-flavored solution, 200 mL/bottle	No

Generic Available?

Other Reference Links

National HIV Curriculum

U.S. Guidelines Links

Clinical Info Drug Database

FDCs

Darunavir / Cobicistat

Darunavir / Cobicistat / Emtricitabine / Tenofovir alafenamide

Assistance Programs

Janssen Care Path

Displaying 1 - 100 of 186

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Rilpivirine (IM) Darunavir/ritonavir	Green: Administer standard doses	Administer standard doses
Darunavir Erythromycin 1033	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of antibacterial adverse effects				Use alternative agents
Darunavir Betrixaban 1032	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased bleeding risk				No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Darunavir Dexamethasone 1031	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential loss of antiviral efficiacy			Not studied	Monitor viral load if extended dexamethasone use. Consider alternative corticosteroid for long-term use.
Darunavir Dextromethrophan 1030	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased dextromethorphan effects	Not reported	30 mg x 1	Cmax increase 127%, AUC increase 170%	Monitor for dextromethorphan adverse effects
Darunavir CBZ 1029	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased carbamazepine effects	Darunavir: No significant change; Ritonavir cmax decreased 44%, AUC decreased 49%, Cmin decreased 56%	200 mg BID	Cmax increase 43%, AUC increase 45%, Cmin increase 54%	Monitor anticonvulsant level and adjust accordingly. Consider carbamazepine dose reduction by 25-50%. Monitor antiviral efficacy
Darunavir Timolol 1028	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of timolol adverse effects				If coadministering, use caution and clinical monitoring is recommended
Darunavir Metoprolol 1027	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of metoprolol adverse effects				If coadministering, use caution and clinical monitoring is recommended
Darunavir Carvedilol 1026	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of carvedilol adverse effects				If coadministering, use caution and clinical monitoring is recommended
Darunavir Diltiazem 1025	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of diltiazem adverse effects				If coadministering, titrate to effect and monitor diltiazem adverse effects
Darunavir Verapamil 1024	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of verapamil adverse effects				If coadministering, monitor verapamil adverse effects
Darunavir Lidocaine 1023	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of lidocaine adverse effects				If coadministering use with caution and monitor for lidocaine toxicity. Consider therapeutic drug monitoring and ECG if used systemically.
Darunavir Ziprasidone 1022	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of ziprasidone adverse effects				If coadministering, monitor for adverse effects
Darunavir Nefazodone 1021	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nefazodone adverse effects				If coadministering, monitor for adverse effects
Darunavir Ethosuximide 1020	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of ethosuximide adverse effects				If coadministering, monitor for adverse effects
Darunavir Felodipine 1019	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of felodipine adverse effects (e.g. hypotension, bradycardia)				If coadministering, monitor felodipine adverse effects
Darunavir Quinidine 1018	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of quinidine adverse effects (e.g. cardiac arrhythmias, exacerbation of heart failure)				If coadministering, monitor and adjust quinidine as indicated
Darunavir Nifedipine 1017	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased nifedipine effects (e.g. hypotension, bradycardia)				If coadministering, monitor and adjust nifedipine as indicated
Darunavir Nicardipine 1016	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased nicardipine effects (e.g. hypotension, heart block)				If coadministering, monitor and adjust nicardipine as indicated
Darunavir Amlodipine 1015	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of amlodipine adverse effects (e.g. hypotension, bradycardia)				If coadministering, monitor amlodipine adverse effects
Darunavir Zolpidem 1014	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of zolpidem adverse effects				If coadministering, initiate zolpidem at low dose and titrate to effect
Darunavir Trazodone 1013	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of trazodone adverse effects (e.g. nausea, dizziness, hypotension, syncope)				If coadministering, initiate trazodone at low dose. Monitor for CNS and cardiovascular effects.
Darunavir Nortiptyline 1012	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nortriptyline adverse effects				If coadministering, initiate nortriptyline at low dose. Monitor for CNS and cardiovascular effects.
Darunavir CsA 1011	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of cyclosporine adverse effects (supratherapeutic immunosuppression, renal toxicity)	Not studied		Not studied (may increase cyclosporine levels)	If coadministering, initiate lower dose of immunosuppressant, monitor concentrations and toxicity, consult with specialist, and adjust dose as necessary
Darunavir Imipramine 1010	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of imipramine adverse effects				If coadministering, initiate imipramine at low dose. Monitor for CNS and cardiovascular effects.
Darunavir Estazolam 1009	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of estazolam adverse effects				If coadministering, initiate estazolam at low dose and titrate to effect
Darunavir Diazepam 1008	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of diazepam adverse effects				If coadministering, initiate diazepam at low dose and titrate to effect
Darunavir Desipramine 1007	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of desipramine adverse effects (e.g. nausea, dizziness, hypotension, syncope)				If coadministering, initiate desipramine at low dose. Monitor for CNS and cardiovascular effects.
Darunavir Buspirone 1006	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of busprione adverse effects				If coadministering, initiate buspirone at low dose and titrate to effect
Darunavir Terazosin 1005	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of terazosin adverse effects				If coadministering, initiate at lowest dose and titrate while monitoring for clinical response / adverse effects
Darunavir Doxazosin 1004	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of doxazosin adverse effects				If coadministering, initiate at lowest dose and titrate while monitoring for clinical response / adverse effects
Darunavir Amitriptyline 1003	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of amitriptyline adverse effects				If coadministering, initiate amitriptyline at low dose. Monitor for CNS and cardiovascular effects.
Darunavir Tacrolimus 1002	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of tacrolimus adverse effects	Not studied		Not studied (may increase tacrolimus levels)	If coadministering, consider initiating lower immunosuppressant dose. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
Darunavir Sirolimus 1001	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of sirolimus adverse effects (supratherapeutic immunosuppression)	Not studied		Not studied (may increase rapamycin levels)	If coadministering, consider initiating lower immunosuppressant dose. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
Darunavir Artemether / Lumefantrine 1000	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Clinical significance unknown	No significant change	80 / 480 mg	AUC decrease 16%; AUC increase 175%	If coadministering monitor closely for anti- malarial efficacy and lumefantrine toxicity. Dose adjustment not established.
Darunavir Ketoconazole 999	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased darunavir and ketoconazole adverse effects		200 mg BID		Dose adjustment not established; if co-administration needed, ketoconazole dose should not exceed 200 mg daily
Darunavir Itraconazole 998	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased darunavir and itraconazole effects				Dose adjustment not established; if co-administration needed, itraconazole dose should not exceed 200 mg daily
Darunavir Posaconazole 997	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of darunavir and posaconazole adverse effects				Dose adjustment not established, monitor for increased DRV and / or antifungal adverse reactions
Darunavir Isavuconazole 996	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of darunavir and isavuconazole adverse effects				Dose adjustment not established, monitor for increased DRV and / or antifungal adverse reactions
Darunavir Drospirenone / Ethinyl estradiol 995	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of drospirenone adverse effects (hyperkalemia) or decreased contraceptive efficacy				Clinical monitoring is recommended
Darunavir Clonazepam 994	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of clonazepam adverse effects				Clinical monitoring is recommended
Darunavir EVG/c 993	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased or increased elvitegravir, cobicistat, and / or darunavir effects	Cmin decreased 21%	150 / 150 mg once daily	Elvitegravir AUC decrease 20%, Cmin decrease 52%; Cobicistat AUC decrease 15-20%	Use alternative agents. One study supports clinical use of elvitegravir / cobicistat with darunavir 800 mg daily in treatment experienced patients.
Darunavir Salmeterol 992	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of salmeterol adverse effects				Use alternative agents
Darunavir Alprazolam 991	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of alprazolam adverse effects				Use alternative agents
Darunavir Rivaroxaban 990	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Use alternative agents
Darunavir Prasugrel 989	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased antiplatelet activity				Use alternative agents
Darunavir Midazolam 988	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of midazolam adverse effects (e.g. increased sedation, confusion, respiratory depression)				Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) is contraindicated
Darunavir Tamsulosin 987	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of tamsulosin adverse effects				If coadministering, monitor for clinical toxicities
Darunavir Nilotinib 986	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of nilotinib adverse effects				If coadministering, decrease dose or adjust dosing interval as needed
Darunavir Dasatinib 985	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of dasatinib adverse effects				If coadministering, decrease dose or adjust dosing interval as needed
Darunavir Amiodarone 984	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of amiodarone adverse effects (e.g. hypotension, bradycardia, cardiac arrhythmias)				If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
Darunavir Apixaban 983	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Do not coadminister in patients who require apixaban 2.5 mg twice daily. In patients requiring apixaban 5 mg or 10 mg twice daily, reduce apixaban dose by 50%
Darunavir Quetiapine 982	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of quetiapine adverse effects				Consider using alternative agents. If coadministering, reduce quetiapine dose to 1 / 6 of current dose and monitor for quetiapine adverse reactions
Darunavir Vincristine 981	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of vincristine adverse effects				Consider temporarily withholding cobicistat-containing ARV regimen in patients who develop significant hematologic or gastrointestinal adverse effects. If ARV regimen must be withheld for a prolonged period of time, initate a revised regimen
Darunavir Vinblastine 980	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of vinblastine adverse effects				Consider temporarily withholding cobicistat-containing ARV regimen in patients who develop significant hematologic or gastrointestinal adverse effects. If ARV regimen must be withheld for a prolonged period of time, initate a revised regimen
Darunavir Oxcarbazepine 979	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiviral efficacy				Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended
Darunavir Eslicarbazepine 978	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiviral efficacy				Consider alternate anticonvulsants. If coadministering, use caution and clinical monitoring is recommended
Darunavir Tramadol 977	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of tramadol adverse effects				Clinical monitoring is recommended. Dose reduction may be needed
Darunavir Oxycodone 976	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of oxycodone adverse effects (e.g. respiratory depression)				Clinical monitoring is recommended
Darunavir Fentanyl 975	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of fentanyl adverse effects (e.g. respiratory depression)				Clinical monitoring is recommended
Darunavir Triamcinolone 974	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Mometasone 973	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Methylprednisolone 972	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Ciclesonide 971	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Betamethasone 970	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Budesonide 969	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents, particularly for long term use
Darunavir Fluticasone 968	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression)				Avoid combination or use alternative agents
Darunavir Rivaroxaban 967	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination; use alternative anticoagulant
Darunavir Apixaban 966	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination; use alternative anticoagulant
Darunavir Vorapaxar 965	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination and use alternative antiplatelet agent
Darunavir Ticagrelor 964	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination and use alternative antiplatelet agent
Darunavir Dabigatran 963	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased bleeding risk				Avoid combination and use alternative anticoagulant
Darunavir Phenytoin 962	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiviral efficacy, Potential for decreased phenytoin effects				Avoid combination and use alternative agents. If coadministering, monitor and adjust phenytoin levels as indicated and monitor viral load.
Darunavir Phenobarbital 961	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiviral efficacy, Potential for decreased phenobarbital effects				Avoid combination and use alternative agents. If coadministering, monitor and adjust phenytoin levels as indicated and monitor viral load.
Darunavir Voriconazole 960	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased voriconazole effects				Avoid coadministering with boosted protease inhibitors unless benefit outweighs risks. If coadministering, consider therapeutic drug monitoring.
Darunavir Ethinyl estradiol / Norethindrone acetate 959	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and norethindrone	Potential decreased ethinyl estradiol and norethindrone effects (e.g. contraceptive failure)	No significant change	35 mcg / 1.0 mg once daily	Ethinyl estradiol: Cmax decrease 32%, AUC decrease 44%, Cmin decrease 62%; Norethindrone: Cmax decrease 10%, AUC decrease 14%, Cmin decrease 30%	Use alternative agents. If coadministering, back-up contraceptive methods are recommended.
Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 958	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Potential decreased anti-HCV and anti-HIV efficacy	Darunavir Cmax decreased 8%; AUC decreased 24%; Cmin decreased 48%	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax increase 10%, AUC decrease 6%, Cmin increase 10%; Ombitasvir Cmax and AUC decrease 14%, Cmin decrease 13%; Paritaprevir Cmin increase 54%, AUC increase 29%, Cmin increase 30%	Use alternative agents
Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 957	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Potential decreased anti-HCV and anti-HIV efficacy	Cmax decrease 21%, AUC increase 34%, Cmin decrease 46%	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax decrease 25%, AUC decrease 28%, Cmin decrease 35%; Ombitasvir Cmax, AUC, and Cmin decrease 13%; Paritaprevir Cmax decrease 30%, AUC decrease 19%, Cmin increase 59%	Use alternative agents
Darunavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 956	Red: Avoid combination	Do not coadminister: Reduced levels of darunavir	Potential decreased anti-HCV and anti-HIV efficacy	Cmax decrease 13%, AUC decrease 20%, Cmin decrease 43%	250 mg BID + 25 / 150 / 100 mg once daily	Dasabuvir Cmax decrease 16%, AUC decrease 27%; Cmin decrease 46%; Ombitasvir Cmax decrease 24%, AUC and Cmin decrease 27%; Paritaprevir Cmax decrease 30%, AUC decrease 41%, Cmin decrease 17%	Use alternative agents
Darunavir Phenytoin 955	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Darunavir Phenobarbital 954	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Darunavir St. John's Wort (Hypericum perforatum) 953	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Darunavir CBZ 952	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Darunavir RIF 951	Red: Avoid combination	Do not coadminister: Potential for reduced levels of darunavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Darunavir Suvorexant 950	Red: Avoid combination	Do not coadminister: Potential for increased suvorexant levels	Potential for increased risk of suvorexant adverse effects				Use alternative agents
Darunavir Perphenazine 949	Red: Avoid combination	Do not coadminister: Potential for increased perphenazine levels	Potential for increased risk of perphenazine adverse effects				Contraindicated. Use alternative agents.
Darunavir Naloxegol 948	Red: Avoid combination	Do not coadminister: Potential for increased naloxegol levels	Potential for increased risk of precipitating opioid withdrawal				Contraindicated. Use alternative agents.
Darunavir Mexiletine 947	Red: Avoid combination	Do not coadminister: Potential for increased mexiletine levels	Potential for increased risk of mexiletine adverse effects				Use alternative agents
Darunavir Lurasidone 946	Red: Avoid combination	Do not coadminister: Potential for increased lurasidone levels	Potential for increased risk of lurasidone adverse effects				Contraindicated. Use alternative agents.
Darunavir Triazolam 945	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Potential for increased risk of triazolam adverse effects (e.g. increased sedation, confusion, respiratory depression)				Contraindicated. Use alternative agents.
Darunavir Terfenadine 944	Red: Avoid combination	Do not coadminister: Potential for increased levels of terfendaine	Potential for increased risk of terfenadine adverse effects (e.g. cardiac arrhythmias)				Use alternative agents
Darunavir Simvastatin 943	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Increased risk of simvastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Not studied		Not studied (may increase simvastatin levels)	Contraindicated. Use alternative agents.
Darunavir Silodosin 942	Red: Avoid combination	Do not coadminister: Potential for increased levels of silodosin	Potential for increased risk of silodosin adverse effects				Contraindicated. Use alternative agents.
Darunavir Ranolazine 941	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine and darunavir	Potential for increased risk of ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias)				Use alternative agents
Darunavir Pimozide 940	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Potential for increased risk of pimozide adverse effects (e.g. hypotension, cardiac arrhythmias)				Contraindicated. Use alternative agents.
Darunavir HMG-CoA Reductase Inhibitors 939	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Increased risk of lovastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Not studied		Not studied (may increase lovastatin levels)	Contraindicated. Use alternative agents.
Darunavir Lomitapide 938	Red: Avoid combination	Do not coadminister: Potential for increased levels of lomitapide	Potential for increased risk of lomitapide adverse effects	Not studied		Not studied	Contraindicated. Use alternative agents.
Darunavir Ergotamine 937	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potential for increased risk of ergotamine adverse effects (e.g. peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Darunavir Dofetilide 936	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Potential for increased risk of dofetilide adverse effects				Use alternative agents
Darunavir Disopyramide 935	Red: Avoid combination	Do not coadminister: Potential for increased levels of disopyramide	Potential for increased risk of disopyramide adverse effects				Use alternative agents

Subscribe to Darunavir